FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer By Ogkologos - September 9, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1 Source RELATED ARTICLESMORE FROM AUTHOR Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian MOST POPULAR Is CBD Safe for People With Cancer? September 22, 2020 EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp August 13, 2020 Coronavirus reports – Part 6 “The kids being home all the... July 17, 2020 ESMO 2024 Press Conference September 13, 2024 Load more HOT NEWS ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research,... New on NCI Websites for July 2019 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... EMA Recommends Extension of Indications for Avelumab
